EP
TGTX icon

Eversept Partners’s TG Therapeutics TGTX Stock Holding History

Eversept Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-41,500
Closed -$461K – 78
2019
Q4 		$461K Buy
+41,500
New +$316K 0.08% 68

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's TGTX Position: Q3 2021 in Review

Eversept Partners sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 69,760 shares — an estimated $2.71M sold.

Eversept Partners first reported a position in TGTX in Q1 2018 and held it in 14 quarters. The position peaked at $48.7M in Q2 2020. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

  • Eversept Partners reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Eversept Partners sold 69,760 TG Therapeutics shares in Q3 2021, an estimated $2.71M.
  • Eversept Partners first reported a position in TG Therapeutics in Q1 2018 and held it in 14 quarters.
  • Eversept Partners's TG Therapeutics position peaked at $48.7M in Q2 2020.
  • 222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.